Your browser is no longer supported. Please, upgrade your browser.
Settings
DEPO Depomed, Inc. daily Stock Chart
DEPO [NASD]
Depomed, Inc.
Index- P/E- EPS (ttm)-1.26 Insider Own0.60% Shs Outstand63.98M Perf Week-4.61%
Market Cap1.06B Forward P/E10.87 EPS next Y1.52 Insider Trans-11.11% Shs Float60.43M Perf Month18.82%
Income-75.70M PEG- EPS next Q0.18 Inst Own- Short Float25.30% Perf Quarter1.60%
Sales342.70M P/S3.09 EPS this Y-161.40% Inst Trans-0.33% Short Ratio7.41 Perf Half Y-12.44%
Book/sh5.20 P/B3.18 EPS next Y18.26% ROA-6.40% Target Price23.17 Perf Year-29.20%
Cash/sh3.28 P/C5.04 EPS next 5Y16.00% ROE-22.20% 52W Range12.25 - 33.74 Perf YTD-8.77%
Dividend- P/FCF7.44 EPS past 5Y19.13% ROI- 52W High-50.98% Beta1.24
Dividend %- Quick Ratio1.40 Sales past 5Y33.50% Gross Margin80.20% 52W Low35.02% ATR0.89
Employees494 Current Ratio1.40 Sales Q/Q-42.90% Oper. Margin-14.70% RSI (14)50.27 Volatility5.98% 5.35%
OptionableYes Debt/Eq2.60 EPS Q/Q-141.10% Profit Margin-22.10% Rel Volume1.09 Prev Close16.80
ShortableYes LT Debt/Eq2.60 EarningsMay 05 AMC Payout- Avg Volume2.06M Price16.54
Recom2.10 SMA20-1.13% SMA506.59% SMA200-17.44% Volume2,243,500 Change-1.55%
Apr-11-16Reiterated Mizuho Neutral $14 → $18
Mar-24-16Reiterated Mizuho Neutral $16 → $14
Mar-24-16Initiated Northland Capital Outperform
Mar-10-16Initiated Leerink Partners Outperform $21
Feb-25-16Reiterated Mizuho Buy $19 → $16
Feb-24-16Reiterated WallachBeth Buy $33 → $27
Feb-23-16Reiterated RBC Capital Mkts Sector Perform $26 → $24
Feb-08-16Initiated Piper Jaffray Overweight
Jan-07-16Initiated Mizuho Neutral $19
Dec-03-15Resumed Morgan Stanley Equal-Weight $21
Nov-11-15Upgrade WallachBeth Hold → Buy $33
Nov-11-15Reiterated ROTH Capital Buy $21 → $24
Nov-04-15Initiated Cantor Fitzgerald Buy
Oct-21-15Reiterated RBC Capital Mkts Sector Perform $32 → $26
Jul-30-15Downgrade RBC Capital Mkts Outperform → Sector Perform $26 → $32
Jul-24-15Reiterated WallachBeth Hold $26 → $33
Jul-14-15Reiterated ROTH Capital Buy $28.50 → $33
Jun-11-15Initiated Morgan Stanley Equal-Weight $23
May-12-15Reiterated RBC Capital Mkts Outperform $29 → $26
Apr-22-15Initiated Piper Jaffray Overweight $37
May-05-16 07:07AM  Q1 2016 Depomed Inc Earnings Release - After Market Close CCBN
May-04-16 06:26PM  TABLE-Hedge fund managers' investment picks from Sohn conference Reuters
06:06PM  Sohn Conference: Jeff Smith Pitches Depomed (DEPO), Westrock (WRK) at Insider Monkey
04:24PM  Jeffrey Smith Says It's Time to Buy Depomed and WestRock: Sohn 2016 at TheStreet
02:40PM  Starboard's Smith targeting pharma firm for proxy fight at CNBC
12:40PM  What Caused DepoMed's Shares to Skyrocket 20.9% In April at Motley Fool
May-03-16 08:00AM  Depomed to Present at Healthcare Conferences in May GlobeNewswire
Apr-28-16 08:00AM  Depomed to Report First Quarter Fiscal Year 2016 Financial Results on Thursday, May 5, 2016 GlobeNewswire +5.13%
Apr-27-16 12:16PM  4 Bargain Stocks You Can Buy Today at Motley Fool
12:11PM  Sohn Preview: Starboard Value Adds Infoblox to Already Full Plate at TheStreet
Apr-25-16 12:42PM  [$$] Depomed Says Starboard Has Month to Call Shareholder Meeting at The Wall Street Journal
11:02AM  Depomed gives Starboard chance for meeting to replace board AP
07:54AM  Depomed says Starboard has a month to request for shareholder meeting Reuters
07:01AM  DEPOMED INC Files SEC form 8-K, Other Events EDGAR Online
06:30AM  Depomed Announces Record Date to Determine Shareholders Entitled to Request Special Meeting GlobeNewswire
Apr-19-16 12:24PM  Why This Hedge Fund Activist Wants to Replace Yahoos Entire Board at Fortune
Apr-18-16 03:00PM  Activist shareholder: Board change 'required' at East Bay drug company at bizjournals.com
Apr-16-16 08:58PM  Depomed Inc (DEPO): Starboard Value Snatches Up Another 1.5 Million Shares at Insider Monkey
Apr-15-16 02:03PM  Activist Investor Reaffirms Stance On Depomed, Says 'Meaningful Change Is Needed'
12:10PM  East Bay drug company avoids 'distracting' shareholder fight by withdrawing reincorporation plan at bizjournals.com
10:43AM  [$$] Starboard to Continue Proxy Fight Against Depomed at The Wall Street Journal
10:15AM  Starboard presses on with push to replace Depomed's board
09:40AM  Stocks to Watch: Citigroup, Mitel Networks, Bats Global at The Wall Street Journal
07:56AM  Starboard says to continue to push for board change at Depomed
07:15AM  Starboard Comments On Depomed's Decision To Withdraw Its Reincorporation Proposal PR Newswire
Apr-14-16 07:20PM  After Hours: Apple App Store Changes, Valeant Mulls Options, BATS IPO
06:33PM  [$$] Depomed Abandons Plans to Reincoporate in Delaware at The Wall Street Journal
05:38PM  Depomed not to reincorporate to Delaware from California
04:56PM  Depomed Announces Decision Not To Pursue Proposed Reincorporation PR Newswire
09:45AM  Why You Should Pay Attention to Activist Jeff Smiths Latest Moves at Insider Monkey
Apr-13-16 08:06PM  [$$] Depomed Faces an Uphill Slog on Starboard Campaign at The Wall Street Journal
Apr-12-16 04:01PM  Why One Activist Thinks This Company Is Too Cheap at Motley Fool
10:37AM  Dealpolitik: Starboard Campaign Is Bitter Pill for Depomed at The Wall Street Journal
Apr-11-16 04:15PM  A Look Into Jeff Smith, John Paulson & Two Other Investors Latest Moves at Insider Monkey
08:11AM  Depomed, Inc. breached its 50 day moving average in a Bullish Manner : DEPO-US : April 11, 2016
12:18AM  [$$] Business Watch at The Wall Street Journal
Apr-08-16 06:01PM  East Bay drug company pushed again to sell this time from the inside at bizjournals.com +13.00%
05:08PM  Starboard attempts a coup at Depomed
02:32PM  Depomed Responds To Activist Investor, Notes Starboard Has Made No Contact With Management
02:06PM  Starboard Value Takes Aim at a New Activist Target, Plus All the Details on 3 Other Filings at Insider Monkey
12:23PM  Activist Sinks Teeth Into Depomed, Send Shares Soaring 12% Today at Motley Fool
11:06AM  Starboard urges Depomed board to pursue a potential sale
11:05AM  Egregious Depomed Soars After Activist Starboard Targets Drugmaker
10:43AM  Starboard says Depomed should consider selling itself at MarketWatch
10:15AM  [$$] Starboard Says Depomed Should Consider Selling Itself at The Wall Street Journal
10:05AM  Why Depomed Is Rising on Activist Pressure at 24/7 Wall St.
09:53AM  DepoMed's stock soars on heavy volume after Starboard discloses stake at MarketWatch
09:26AM  Deals of the Day: Vivendi Eyes Mediaset, Starboard Targets DepoMed at The Wall Street Journal
09:06AM  Depomed Issues Statement in Response to Starboard Value LP 13D Filing PR Newswire
08:59AM  DepoMed (DEPO) Stock Surging as Starboard Takes Stake at TheStreet
08:01AM  Starboard Delivers Letter to Depomed CEO and Board of Directors PR Newswire
07:46AM  Early movers: YHOO, ULTA, CBS, LNKD, MET & more at CNBC
12:46AM  PRESS DIGEST- New York Times business news - April 8 Reuters
Apr-07-16 06:08PM  Depomed Activist Starboard Value Seeking Control of Board at Bloomberg
06:07PM  Depomed jumps after activist investor Starboard Value takes stake at MarketWatch
Apr-04-16 04:08PM  DEPOMED INC Files SEC form 8-K, Other Events
04:00PM  Depomed Announces Prepayment of $100 Million of Secured Debt Facility GlobeNewswire
10:55AM  Key Analyst Sees Huge Catalyst in Depomed Patent Suit at 24/7 Wall St.
Mar-24-16 04:56PM  Appeals Court Upholds Depomed Patents Asserted against Purdue Pharma at noodls
04:29PM  Appeals Court Upholds Depomed Patents Asserted against Purdue Pharma GlobeNewswire
09:21AM  If It Wasn't For Pfizer, Allergan Investors Might Be Getting Pummeled at Motley Fool
08:56AM  Coverage initiated on DepoMed by Northland Capital
Mar-23-16 11:51AM  DEPOMED INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Mar-22-16 10:26PM  3 Beaten-Up Healthcare Stocks: Are They Bargains? at Motley Fool
Mar-14-16 04:58PM  DEPOMED INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:23AM  Depomed, Inc. breached its 50 day moving average in a Bullish Manner : DEPO-US : March 14, 2016
Mar-10-16 04:32PM  Depomed (DEPO) Stock Receives Outperform Rating at Leerink at TheStreet
08:55AM  Top Analyst Upgrades and Downgrades: DepoMed, Enterprise Products, Expedia, Netflix, Sunrun, Vale and More at 24/7 Wall St.
08:00AM  Depomed to Host Analyst and Investor Day on Wednesday, March 23 GlobeNewswire
Mar-07-16 08:00AM  Depomed to Present at 28th Annual ROTH Conference GlobeNewswire
Mar-06-16 02:00PM  3 Underdog Stocks We're Watching at Motley Fool
Mar-04-16 12:07AM  Sizing up GlaxoSmithKlines Consumer Healthcare Segment
Mar-03-16 01:04PM  DEPOMED INC Financials
Feb-29-16 08:36AM  Depomed, Inc. breached its 50 day moving average in a Bearish Manner : DEPO-US : February 29, 2016 -6.54%
08:00AM  Cebranopadol Top-Line Data From Phase IIb Trial in Chronic Lower Back Pain Demonstrate Clinically and Statistically Significant Improvements in Pain Across All Arms GlobeNewswire
Feb-26-16 09:56PM  DEPOMED INC Files SEC form 10-K, Annual Report
09:45AM  DEPO: NUCYNTA Continued Momentum in 4Q15
Feb-24-16 11:22AM  Depomed, Inc. Earnings Analysis: 2015 By the Numbers
Feb-23-16 03:23AM  Edited Transcript of DEPO earnings conference call or presentation 22-Feb-16 9:30pm GMT
Feb-22-16 06:07PM  Depomed reports 4Q loss
04:30PM  Depomed Inc Earnings Call scheduled for 4:30 pm ET today
04:08PM  DEPOMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:00PM  Depomed Reports Record Fourth Quarter and Full Year 2015 Financial Results GlobeNewswire
08:30AM  Healthcare Booming for Synergy, DepoMed, Novo Nordisk and United Therapeutics Accesswire
07:07AM  Q4 2015 Depomed Inc Earnings Release - After Market Close
Feb-19-16 04:09PM  DEPOMED INC Files SEC form 8-K, Change in Directors or Principal Officers
Feb-18-16 08:12AM  Depomed, Inc. breached its 50 day moving average in a Bullish Manner : February 18, 2016
Feb-16-16 08:00AM  Depomed to Report Fourth Quarter Fiscal Year 2015 Financial Results on Monday, February 22, 2016 GlobeNewswire
Feb-14-16 07:41AM  3 Under-Appreciated Healthcare Stocks I Still Love at Motley Fool
Feb-09-16 10:51AM  UBS Starts Depomed At Buy, Says Nucynta Has More Potential Than Market Thinks
Feb-08-16 08:00AM  Depomed Announces Favorable Markman Ruling in Nucynta® and Nucynta® ER Patent Litigation GlobeNewswire -5.70%
Feb-03-16 08:00AM  Depomed to Present at Healthcare Conferences in February GlobeNewswire
Jan-27-16 08:26AM  Depomed Announces Save the Date for 2016 Analyst and Investor Day at noodls -8.78%
08:00AM  Depomed Announces Save the Date for 2016 Analyst and Investor Day GlobeNewswire
Jan-21-16 04:15PM  Depomed, Inc.: Price momentum supported by strong fundamentals
Jan-19-16 08:01AM  DEPOMED INC Files SEC form 8-K, Other Events -7.12%
Jan-14-16 10:20AM  The #JPM16 wrap: A new reality, Invitae's big test and Horizon's silence at bizjournals.com +6.33%
Jan-06-16 08:02AM  Why Horizon Pharma plc Shares Jumped 68% in 2015 at Motley Fool
Jan-04-16 08:00AM  Depomed Announces Closing of Acquisition of U.S. Rights to Cebranopadol From Grunenthal GlobeNewswire
Dec-29-15 08:11AM  Depomed, Inc. breached its 50 day moving average in a Bearish Manner : December 29, 2015
Depomed, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; and Lazanda (fentanyl) nasal spray, an intranasal fentanyl drug used to manage breakthrough pain in adults. The company also provides NUCYNTA ER (tapentadol extended release tablets), a product for the management of pain severe enough to long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults; and NUCYNTA (tapentadol), a product for the management of moderate to severe acute pain in adults. In addition, it is involved in the clinical development of IW-3718 refractory gastroesophageal reflux disease program using Acuform drug delivery technology; and Cebranopadol, a molecule for the treatment of chronic nociceptive and neuropathic pain. Depomed, Inc. sells its Gralise products to wholesalers and retail pharmacies. The company also has a portfolio of license agreements based on its proprietary Acuform gastroretentive drug delivery technology with Mallinckrodt Inc.; Ironwood Pharmaceuticals, Inc.; and Janssen Pharmaceuticals, Inc. The company was founded in 1995 and is headquartered in Newark, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schoeneck James APresident and CEOMar 18Option Exercise3.9430,483120,09436,848Mar 21 04:17 PM
Vargas Thadd MSenior VP, BDMar 11Sale16.0023,000368,000137,737Mar 11 06:40 PM
Vargas Thadd MSVP, Business DevelopmentMar 02Sale15.1810,000151,780160,737Mar 04 08:28 PM
Vargas Thadd MSVP, Business DevelopmentJan 11Option Exercise7.1218,180129,442170,737Jan 12 07:10 PM
Schoeneck James APresident and CEODec 28Option Exercise6.116,36538,8906,365Dec 28 07:24 PM
Moretti August JChief Financial Officer & SVPDec 16Option Exercise5.355,00026,75026,319Dec 17 12:31 PM
Moretti August JChief Financial Officer & SVPDec 03Sale18.1115,000271,59721,319Dec 03 06:32 PM
Schoeneck James APresident and CEOSep 29Option Exercise6.4263,561408,15863,561Sep 29 07:24 PM
Vargas Thadd MSenior VP, BDJun 12Sale20.705,000103,500138,153Jun 15 05:16 PM
STAPLE PETER DDirectorMay 12Option Exercise6.1810,00061,80060,000May 12 09:23 PM
Schoeneck James APresident and CEOMay 12Option Exercise6.6645,679304,13461,411May 12 09:21 PM